Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centered, Randomized, Open-label Phase III Study to Evaluate the Efficacy and Safety of TGRX-326 Comparing With Crizotinib in Patients of Advanced ALK-positive or Metastatic Non-Small Cell Lung Cancer

NCT06082635 is registered in ClinicalTrials.gov with Shenzhen TargetRx Co., Ltd. as lead sponsor.

NCT NCT06082635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06082635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centered, Randomized, Open-label Phase III Study to Evaluate the Efficacy and Safety of TGRX-326 Comparing With Crizotinib in Patients of Advanced ALK-positive or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
Shenzhen TargetRx Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 14, 2023
Completion date
November 30, 2028
Enrollment
321 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer